Cargando…

TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancers and remains the most common cause of cancer-related death. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have been used as first-line treatment for patients with NSCLC showing EGFR mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Zhangxian, Li, Mingxi, Zhang, Xiaoqian, Rong, Xuezhu, Xu, Hongtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035062/ https://www.ncbi.nlm.nih.gov/pubmed/36896765 http://dx.doi.org/10.3892/or.2023.8521

Ejemplares similares

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line
por: Nishimura, Yukio, et al.
Publicado: (2008)

DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity
por: Hama, Taketsugu, et al.
Publicado: (2021)

TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription
por: Yuan, Weiwei, et al.
Publicado: (2019)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Overexpression of TRAF4 promotes lung cancer growth and EGFR‐dependent phosphorylation of ERK5
por: He, Siwei, et al.
Publicado: (2022)

TRIP13 overexpression in hepatocellular carcinoma: implications for poor prognosis and immune cell infiltration
por: Xue, Jiapeng, et al.
Publicado: (2023)

Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer
por: Li, Bin, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway
por: Gao, Yanjun, et al.
Publicado: (2019)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy
por: Liu, Yuhong, et al.
Publicado: (2022)

TRIP 13-dependent pathways promote the development of gastric cancer
por: Ni, Fengming, et al.
Publicado: (2023)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway
por: Lu, Rujian, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Disassembly of the Shieldin Complex by TRIP13
por: Sarangi, Prabha, et al.
Publicado: (2020)

WW and C2 domain-containing protein-3 promoted EBSS-induced apoptosis through inhibiting autophagy in non-small cell lung cancer cells
por: Han, Qiang, et al.
Publicado: (2020)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
por: Wang, Debby D., et al.
Publicado: (2015)

Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer
por: Ren, Hui, et al.
Publicado: (2019)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
por: Cho, Jung Hee, et al.
Publicado: (2022)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
por: Britain, Colleen M., et al.
Publicado: (2018)

EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC
por: Meng, Jiao, et al.
Publicado: (2019)

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy
por: Li, Xiao-Qiu, et al.
Publicado: (2016)

Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
por: Han, Shu-Yan, et al.
Publicado: (2014)

TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer
por: Sheng, Nengquan, et al.
Publicado: (2018)

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
por: Bokobza, Sivan M., et al.
Publicado: (2014)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
por: Singh, Charu
Publicado: (2014)

TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non–small‐cell lung cancer
por: Shuai, Shuai, et al.
Publicado: (2021)

Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation
por: Li, Xiaofeng, et al.
Publicado: (2022)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
por: Nio, Yuta, et al.
Publicado: (2022)

TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors
por: Cheong, Jit Kong, et al.
Publicado: (2009)

Trip and Trip Pro
por: Fox, Lynne M.
Publicado: (2018)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_7ki3999s1od3ehq624gs48674n